We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

RNA-Based Gene Therapy Developed for Cystic Fibrosis

By LabMedica International staff writers
Posted on 05 Jul 2018
Image: Structure of the CFTR (cystic fibrosis transmembrane conductance regulator) protein. Mutations of the CFTR gene affecting chloride ion channel function lead to dysregulation of epithelial fluid transport in the lung, pancreas, and other organs, resulting in cystic fibrosis (Photo courtesy of Wikimedia Commons).
Image: Structure of the CFTR (cystic fibrosis transmembrane conductance regulator) protein. Mutations of the CFTR gene affecting chloride ion channel function lead to dysregulation of epithelial fluid transport in the lung, pancreas, and other organs, resulting in cystic fibrosis (Photo courtesy of Wikimedia Commons).
A potential gene therapy approach for treating cystic fibrosis utilizes lipid nanoparticle-delivered chemically modified mRNA.

The promise of gene therapy for the treatment of cystic fibrosis has yet to be fully clinically realized despite years of effort toward correcting the underlying genetic defect in CFTR (cystic fibrosis transmembrane conductance regulator). Mutations in CFTR cause the disease, which is characterized by lung dehydration and mucous buildup that blocks the airway. Nanoparticle delivery of messenger RNA (mRNA) represents a powerful technology for the transfer of genetic material to cells with large, widespread populations, such as airway epithelia.

Investigators at Oregon State University (Portland, USA) and Oregon Health & Science University (Portland, USA) deployed a clinically relevant lipid-based nanoparticle (LNP) for packaging and delivery of large chemically modified CFTR mRNA (cmCFTR) to patient-derived bronchial epithelial cells.

Results published in the June 14, 2018, online edition of the journal Molecular Therapy revealed that this treatment caused in an increase in membrane-localized CFTR and rescue of its primary function as a chloride channel. Furthermore, nasal application of LNP-cmCFTR restored CFTR-mediated chloride secretion to conductive airway epithelia in CFTR knockout mice for at least 14 days. On day three post-transfection, CFTR activity peaked, recovering up to 55% of the net chloride efflux characteristic of healthy mice. This magnitude of response was superior to liposomal CFTR DNA delivery and was comparable with outcomes observed in the currently approved drug ivacaftor.

"It was a platform technology for correcting monogenic disorders and allows the same therapy to be effective for treating all cystic fibrosis patients and these systems can be repeatedly administered to a patient and the effects are reversible if someone needs to stop the therapy for any reason," said senior author Dr. Gaurav Sahay, assistant professor of pharmaceutical sciences at Oregon State University/Oregon Health & Science University.

Related Links:
Oregon State University
Oregon Health & Science University

Gold Member
Aspiration System
VACUSAFE
Online QC Software
Acusera 24•7
HIV-1 Molecular Diagnostic Assay
AltoStar HIV RT-PCR Kit 1.5
Food Allergy Screening ELISA Kit
Allerquant 14G B ELISA

Channels

Clinical Chemistry

view channel
Image: Researchers use a novel immobilized liposome-bound gel beads method to measure CEC levels and their association with cardiovascular risks (Photo courtesy of Institute of Science Tokyo)

Simple Blood-Based Cholesterol Efflux Assay Identifies High-Risk Coronary Plaque Features

Unstable coronary plaques are difficult to identify before they trigger acute cardiovascular events. Standard high-density lipoprotein (HDL) measurements do not always capture how well HDL particles function... Read more

Pathology

view channel
Image: Overview of the uncertainty-aware lensfree computational pathology platform for automated HER2 assessment. A compact lensfree holographic imaging system captures diffraction patterns from immunohistochemically stained breast tissue samples, which are computationally reconstructed and analyzed using deep neural networks with Bayesian uncertainty quantification. (Photo courtesy of Ozcan Lab, UCLA)

Uncertainty-Aware AI Platform Supports Automated HER2 Assessment in Breast Cancer

Accurate assessment of human epidermal growth factor receptor 2 (HER2) is critical for breast cancer diagnosis and treatment selection, yet scoring variability and infrastructure requirements can complicate... Read more
ADLM